Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
Tag Archive for: gene therapies
The contract manufacturer has been facing challenges at three of its major production sites, which may affect its third and fourth-quarter revenue due to a slower-than-expected ramp up in production capacity.
2022 was a big year for uniQure with the U.S. and European approval of world’s first gene therapy for hemophilia B. In its 2022 financial report Monday, the Lexington, Mass. and Amsterdam-based company provided updates on the progress of its Huntington’s disease and ALS programs.
Monday, Astellas named a new president and CEO and announced additional changes to its leadership structure in an effort to accelerate growth and chart its long-term business trajectory.
Alzheimer’s research is having a moment, and the discovery of novel biomarkers is enabling progress far beyond diagnostics.
The Institute for Clinical and Economic Review (ICER) concluded Tuesday that gene therapies for hemophilia A and B are worth it even at a hefty lifetime cost of $2.5 million.
Adverum Biotechnologies announced Thursday that it is removing 78 jobs, slashing its workforce by 38%. This move is in line with the company’s plan to streamline operations in order to completely fund existing eye disease projects and extend its cash runway into 2025.
Precision BioSciences entered into an exclusive global in vivo gene editing research and development collaboration and license deal with Novartis Pharma. The two companies will work to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
